Immunological mechanisms of cutaneous adverse drug reactions;Mécanismes immunologiques des réactions cutanées aux médicaments

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 2, 2005, Pages 177-183

  Poszepczynska Guigne E ^a   Revuz, J ^a   Roujeau, J C ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; DAPSONE; DRUG; HAPTEN; LIDOCAINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOCYCLINE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; SULFAMETHOXAZOLE; SULFANILAMIDE;

ALLERGY; ANGIONEUROTIC EDEMA; ANTIGEN RECOGNITION; DRUG HYPERSENSITIVITY; DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS SYNDROME; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; PAPULOSIS; REVIEW; SKIN MANIFESTATION; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 15044340000     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(05)79235-8     Document Type: Review

References (60)

1. Yawalkar N, Pichler WJ. Immunohistology of drug-induced exanthema: clues to pathogenesis. Curr Opin Allergy Clin Immunol 2001; 1:299-303.
2. Pichler WJ, Yawalkar N. Allergic reactions to drugs: involvement of T-cells. Thorax 2000;55 (suppl 2):S61-5.
3. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002;3:229-38.
4. Pichler WJ. Deciphering the immune pathomechanism of cutaneous drug reactions, Allergy 2002;57 (suppl 72):34-6.
5. Gonzalez FJ, Leyva L, Posadas S, Luque I, Blanca M, Santamaria L et al. Participation of T lymphocytes in cutaneous allergic reaction to drugs. Clin Exp Allergy 1998;28 (suppl 4):3-6.
6. Hertl M, Merk HF. Lymphocyte activation in cutaneous drug reaction. J Invest Dermatol 1995;105:95S-8S.
7. Merk HF, Hertl M. Immunologic mechanisms of cutaneous drug reaction. Semin Cutan Med Surg 1996;15:228-35.
8. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998;11:969-88.
9. Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992;51:522-6.
10. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000;356:1587-91.
11. Eliaszewicz M, Flahault A, Roujeau JC, Fillet AM, Challine D, Mansouri S et al. Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am Acad Dermatol 2002;47:40-6.
12. Pirmohamed M, Coleman MD, Hussain F, Breckenridge AM, Park BK. Direct and metabolism-dependant toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. Br J Clin Pharmacol 1991;32:303-10.
13. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M. Metabolic predisposition to cutaneous adverse drug reactions. Role of toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995;131:544-51.
14. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y et al. HLA-restricted, processing and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998;102:1591-8.
15. Nassif A, Bensussan A, Dorothee C, Mami-Chouaib F, Bachot N, Bagot M et al. Drug-specific cytotoxic T lymphocytes in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002;118:728-33.
16. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13:114-9.
17. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12: 991-1045.
18. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis -potential role in idiosyncratic drug reactions. Toxicology 2002;181:55-63.
19. Heller HM. Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection. Clin Dermatol 2000;18:485-9.
20. Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensivity syndrome. Arch Dermatol 1998;134:1108-12.
21. Vance RE. Cutting edge commentary: a Copernician revolution? Doubts about the danger theory. J Immunol 2000;165:1725-8.
22. Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dume L et al. Patch-testing in severe cutaneous adverse drug reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35:234-6.
23. Correia O, Delgado L, Ramos JP, Resende C, Fleming Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocytes involvement. Arch Dermatol 1993;129:466-8.
24. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensivity syndrome (Drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7.
25. Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C et al. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991;127:1333-8.
26. Barbaud AM, Béné MC, Schmutz JL, Ehlinger A, Weber M, Faure GC. Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes. Arch Dermatol 1997;133:481-6.
27. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000;30:847-55.
28. Shiohara T, Nickoloff BJ, Sagawa Y, Comi T, Nagashima M. Fixed drug eruption. Expression of epidermal keratinocyte intercellular adhesion molecule-1 (ICAM-1). Arch Dermatol 1989;125:1371-6.
29. Blanca M, Posada S, Torres MJ, Leyva L, Mayorga C, Gonzalez L et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with non immediate cutaneous allergic drug reactions. Allergy 2000; 55:998-1004.
30. Schnyder B, Frutig K, Mauri-Hellweg D, Limat A, Yawalkar N, Pichler WJ. T-cell mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998;28:1412-7.
31. Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000;119:225-30.
32. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
33. Berthou C, Michel L, Soulie A, Jean-Louis F, Flageul B, Dubertret L et al. Acquisition of granzyme B and fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol 1997;159:5293-300.
34. Nagakura N, Kobayashi T, Shimizu T, Masuzawa T, Yanagihara Y. Immunological properties of cephalexin-induced delayed type hypersensitivity reaction in guinea pigs. Chem Pharm Bull (Tokyo)1990;38:3410-3.
35. Hattori H, Yamaguchi F, Furuhama K, Takayama S. Evaluation of delayed type hypersensitivity to beta-lactam antibiotics in mice. J Antimicrob Chemother 1993;31:739-47.
36. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 1995;155:462-72.
37. Hertl M, Geisel J, Boecker C, Merk HF. Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993;128:619-26.
38. Zanni MP, Mauri-Hellweg D, Brander C, Wendland T, Schnyder B, Frei E et al. Characterization of lidocaine-specific T cells. J Immunol 1997;158:1139-48.
39. Naisbitt DJ, Farrell J, Wong C, Depta JP, Dodd CC, Hopkins JE et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003;111: 1393-403.
40. von Greyerz S, Bulteman C, Schnyder K, Burkhart C, Lotti B, Hari Y et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. Int Immunol 2001;13:877-85.
41. Yawalkar N, Shrikhande M, Hari Y, Nevergelt H, Braathen LR, Pichler JW. Evidence for a role for IL-5 and eotaxin in activating and recuiting eosinophilils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106:1171-6.
42. Hashizume H, Takigawa M, Tokura Y. Characterization of drug-specific T cells in phenobabital-induced eruption. J Immunol 2002;168:5359-68.
43. Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mauri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol 1997; 113:177-80.
44. Brugnolo F, Annuziato F, Sampognaro S, Campi P, Manfriedi M, Matucci A et al. Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions. J Immunol 1999;163:1053-9.
45. Kalish RS, LaPorte A, Wood JA, Johnson KL. Sulfonamide-reactive lymphocytes detected at very low frequency in the peripheral blood of patients with drug-induced eruptions. J Allergy Clin Immunol 1994;94:465-72.
46. Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, Svensson CK. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000;114:1164-73.
47. Teraki Y, Moriya N, Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol 1994;145:550-60.
48. Mizukawa Y, Yamazari Y, Teraki Y, Hayakawa J, Hayakawa K, Nuriya H et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol 2002;161:1337-47.
49. Blanca M, Vega JM, Garcia J, Miranda A, Carmona MJ, Juarez C et al. New aspects of allergic reactions to betalactams: cross reactions and unique specificities. Clin Exp Allergy 1994; 24:407-15.
50. Vega JM, Blanca M, Garcia JJ, Carmona MJ, Miranda A, Perez-Estrada M et al. Immediate allergic reactions to amoxicillin. Allergy 1994; 49:317-22.
51. Gutierrez-Ramos JC, Lloyd C, Gonzalo JA. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunol Today 1999;20:500-4.
52. Barbaud A, Bene MC, Reichert-Penetrat S, Jacquin-Petit MA, Schmutz JL, Faure GC. Immunocompetent cells and adhesion molecules in 14 cases of cutaneous drug reactions induced with the use of antibiotics. Arch Dermatol 1998;134:1040-1.
53. Miyauchi H, Hosokawa H, Akaeda T, Iba H, Asada Y. T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells. Arch Dermatol 1991;127:851-5.
54. Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC. Increased levels of Interleukin-5 are associated with the generation of eosinophilia in drug-induced hypersensivity syndrome. Br J Dermatol 1998; 139:1026-32.
55. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001;137:301-4.
56. Schmid S, Kuechler PC, Britschgi M, Steiner UC, Yawalkar N, Limat A et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002;161:2079-86.
57. Britschgi M, Steiner UC, Schmid S, Depta JPH, Senti G, Bircher A et al. T cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001;107:1433-41.
58. Huff JC, Weston WL, Tonnesen MC. Erythema multiforme: a critical review of characteristics, diagnostic criteria and causes. J Am Acad Dermatol 1983;8:763-75.
59. Hindsen M, Christensen OB, Gruic V, Lofberg H. Fixed drug eruption: an immunohistochemical investigation of the acute and healing phase. Br J Dermatol 1987;116:351-60.
60. Komatsu T, Moriya N, Shiohara T. T cell receptor (TCR) repertoire and function of human epidermal T cells: restricted TCR V alpha-V beta genes are utilized by T cells residing in the lesional epidermis in fixed drug eruption. Clin Exp Immunol 1996;104:343-50.